Arnab Basu
@arnabguonc
Followers
605
Following
4K
Media
24
Statuses
971
GU medical oncologist @MayoClinic with an interest in RCC/ Bladder CA and bio marker directed trials. tweets my own views
Florida, USA
Joined January 2018
RT @DrYukselUrun: A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist. #BladderCancer #Oncology #Immunother….
0
53
0
RT @whosainastro: 1/.Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? .If you work in patholo….
0
152
0
RT @VamsiVelcheti: Air pollution harms our patients. @EPA plans to roll back climate and clean air protections—time to speak up. Signing th….
docs.google.com
[DATE] Dear Administrator Zeldin, As health experts we write to share our grave concern at EPA’s effort to rescind dozens of pollution protections for millions, a direct contradiction to the Enviro...
0
2
0
RT @MayoClinic: Today, Mayo Clinic opened the Duan Family Building, taking another step in our journey to introduce carbon ion therapy for….
0
24
0
Tumor informed 🧬 #ctDNA #MRD high concordance with outcomes in #penileCA and #urethralCA , amazing work from rising 🌟 @KartikPatel___ @UABUrology working with @ccp1983 . @ONealCancerUAB @uabmedicine - so more to come from this group!.
Check it out! Utility of ctDNA in locally advanced penile and urethral cancers. Bottom line, ctDNA correlates nicely with clinical response! Perhaps another tool for this uncommon disease. Best part, lead by a super-solid MS4 @KartikPatel___!! @UABUrology .
1
2
8
Excellent work from @Lab_AKundu previously my @uabmedicine colleague now a rising ⭐️ @UAAHGSA , novel 🎯 in #RCC .
A therapeutically actionable novel dependency in RCC has been reported. #kidneycancer, #RenalCellCarcinoma.HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism | Science Advances
0
0
7
RT @ZakhariaYousef: Early phase IIT to suggest favorable outcome with Taxol/CPI in UC. Kudos to @RohanGarjeMD for putting this IIT as 3rd y….
0
7
0
RT @DrBetofMDPhD: I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a we….
0
64
0
RT @StephenVLiu: This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infus….
0
490
0
RT @brian_rini: #ASCO25 HIF inhibitor combination results. Shown below is single agent Cabo and Belzu for reference, and published HIF-base….
0
44
0
RT @AlanBryce9: IMO the most important message here is the importance of paying attention to CV dz for men with advanced PC. Our must do….
0
8
0
RT @crisbergerot: 🧪Exciting science in GU - Kidney & Bladder at #ASCO25!.Don’t miss these cutting-edge posters on:.✅Novel immuno + targeted….
0
11
0
RT @MattGalsky: Our contemporary "negative" RCTs in metastatic UC are just not the same as our "negative" RCTs of the past. Granted a small….
0
4
0
RT @JasonBrownMDPhD: CtDNA exploratory analysis from NIAGARA by @tompowles1 #ASCO25. 👨🔬 CtDNA + decreased after neoadjuvant chemo and prio….
0
4
0
RT @drenriquegrande: Casdatifan, a nivel HIF2alpha inhibitor, on combination with cabozantinib shows promising response rate in pretreated….
0
10
0
RT @GlopesMd: Finding a Hematology/Oncology Job in the United States on a J-1 Visa While Pursuing Your Career Goals | ASCO Connection https….
connection.asco.org
Drs. Akeem Lewis, Ivy Riano, and Rohit Singh offer helpful guidance on navigating the J-1 visa application process to secure a hematology/oncology job in the United States that aligns with personal ca
0
15
0
RT @neerajaiims: Ab#4506 @ASCO #ASCO25 by @DrChoueiri👉�Results from Ph 1 ARC-20 study #kidneycancer👉Casdatifan + Cab….
0
26
0
RT @tompowles1: 1/2 POTOMAC is the last of the 15 PD(L)1 monotherapy IO R3 trials over 10yrs & >8000 pts in bladder cancer. The summary sho….
0
40
0
RT @OncoDailyIO: Cabozantinib Plus PD1 Inhibition Immunotherapy Active - @sonpavde .@EurUrolOncol @AdventHealthCFL @rohitjainMD @maughanonc….
0
4
0